Amgen presented data from the phase II PEAK and phase III PRIME studies evaluating first-line use of Vectibix (panitumumab) in combination with FOLFOX chemotherapy regimen in patients with wild-type RAS metastatic colorectal cancer.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
